Adult living donor versus deceased donor liver transplantation

A 10-year prospective single center experience

Robert A. Fisher, Adrian H. Cotterell, Daniel Maluf, Richard Todd Stravitz, April Ashworth, Mitsuru Nakatsuka, Richard K. Sterling, Velimir A. Luketic, Martha K. Behnke, Marc P. Posner

Research output: Contribution to journalArticle

21 Citations (Scopus)

Abstract

It has been 4 years since the first, long-term (> 3 years) prospective comparison of adult-to-adult living donor liver transplantation (A2ALLTx) to adult deceased donor liver transplantation (ADDLTx) was reported.1 In this follow up, prospective, IRB approved, 10-year comparison of A2ALLTx to ADDLTx we expand on our initial observations. This data includes: age, gender, ethnicity, primary liver disease, waiting time, pretrans-plant CTP/MELD score, cold ischemia time (CIT), perioperative mortality, acute and chronic rejection, graft and patient survival, charges and post-transplant complications. In 10 years, 465 ADDLTx (81.3%) and 107 A2ALLTx (18.7%) were performed at VCUHS. Hepatitis C virus (HCV) was the most common reason for transplantation in both groups (54.5% vs. 48.2%). Data regarding overall patient and graft survival and retransplantation rates were similar. Comparison of patient/graft survivals, retransplantation rates in patients with and without HCV were not statistically different. A2ALLTx patients had less acute rejection (9.6% vs. 21.7%) and more biliary complications (27.1% vs. 17.6%). In conclusion, A2ALLTx is as durable a liver replacement technique as the ADDLTx. Patients with A2ALLTx were younger, had lower MELD scores, less acute rejection and similar histological HCV recurrence. Biliary complications were more common in A2ALLTx but were not associated with increased graft loss compared to ADDLTx.

Original languageEnglish (US)
Pages (from-to)298-307
Number of pages10
JournalAnnals of Hepatology
Volume8
Issue number4
StatePublished - Oct 1 2009

Fingerprint

Living Donors
antineoplaston A10
Liver Transplantation
Tissue Donors
Graft Survival
Hepacivirus
Survival Rate
Transplants
Cold Ischemia
Cytidine Triphosphate
Research Ethics Committees
Liver Diseases
Transplantation
Recurrence
Mortality
Liver

All Science Journal Classification (ASJC) codes

  • Hepatology

Cite this

Fisher, R. A., Cotterell, A. H., Maluf, D., Stravitz, R. T., Ashworth, A., Nakatsuka, M., ... Posner, M. P. (2009). Adult living donor versus deceased donor liver transplantation: A 10-year prospective single center experience. Annals of Hepatology, 8(4), 298-307.

Adult living donor versus deceased donor liver transplantation : A 10-year prospective single center experience. / Fisher, Robert A.; Cotterell, Adrian H.; Maluf, Daniel; Stravitz, Richard Todd; Ashworth, April; Nakatsuka, Mitsuru; Sterling, Richard K.; Luketic, Velimir A.; Behnke, Martha K.; Posner, Marc P.

In: Annals of Hepatology, Vol. 8, No. 4, 01.10.2009, p. 298-307.

Research output: Contribution to journalArticle

Fisher, RA, Cotterell, AH, Maluf, D, Stravitz, RT, Ashworth, A, Nakatsuka, M, Sterling, RK, Luketic, VA, Behnke, MK & Posner, MP 2009, 'Adult living donor versus deceased donor liver transplantation: A 10-year prospective single center experience', Annals of Hepatology, vol. 8, no. 4, pp. 298-307.
Fisher RA, Cotterell AH, Maluf D, Stravitz RT, Ashworth A, Nakatsuka M et al. Adult living donor versus deceased donor liver transplantation: A 10-year prospective single center experience. Annals of Hepatology. 2009 Oct 1;8(4):298-307.
Fisher, Robert A. ; Cotterell, Adrian H. ; Maluf, Daniel ; Stravitz, Richard Todd ; Ashworth, April ; Nakatsuka, Mitsuru ; Sterling, Richard K. ; Luketic, Velimir A. ; Behnke, Martha K. ; Posner, Marc P. / Adult living donor versus deceased donor liver transplantation : A 10-year prospective single center experience. In: Annals of Hepatology. 2009 ; Vol. 8, No. 4. pp. 298-307.
@article{6373e58573e6421d8280444547afddb6,
title = "Adult living donor versus deceased donor liver transplantation: A 10-year prospective single center experience",
abstract = "It has been 4 years since the first, long-term (> 3 years) prospective comparison of adult-to-adult living donor liver transplantation (A2ALLTx) to adult deceased donor liver transplantation (ADDLTx) was reported.1 In this follow up, prospective, IRB approved, 10-year comparison of A2ALLTx to ADDLTx we expand on our initial observations. This data includes: age, gender, ethnicity, primary liver disease, waiting time, pretrans-plant CTP/MELD score, cold ischemia time (CIT), perioperative mortality, acute and chronic rejection, graft and patient survival, charges and post-transplant complications. In 10 years, 465 ADDLTx (81.3{\%}) and 107 A2ALLTx (18.7{\%}) were performed at VCUHS. Hepatitis C virus (HCV) was the most common reason for transplantation in both groups (54.5{\%} vs. 48.2{\%}). Data regarding overall patient and graft survival and retransplantation rates were similar. Comparison of patient/graft survivals, retransplantation rates in patients with and without HCV were not statistically different. A2ALLTx patients had less acute rejection (9.6{\%} vs. 21.7{\%}) and more biliary complications (27.1{\%} vs. 17.6{\%}). In conclusion, A2ALLTx is as durable a liver replacement technique as the ADDLTx. Patients with A2ALLTx were younger, had lower MELD scores, less acute rejection and similar histological HCV recurrence. Biliary complications were more common in A2ALLTx but were not associated with increased graft loss compared to ADDLTx.",
author = "Fisher, {Robert A.} and Cotterell, {Adrian H.} and Daniel Maluf and Stravitz, {Richard Todd} and April Ashworth and Mitsuru Nakatsuka and Sterling, {Richard K.} and Luketic, {Velimir A.} and Behnke, {Martha K.} and Posner, {Marc P.}",
year = "2009",
month = "10",
day = "1",
language = "English (US)",
volume = "8",
pages = "298--307",
journal = "Annals of Hepatology",
issn = "1665-2681",
publisher = "Mexican Association of Hepatology",
number = "4",

}

TY - JOUR

T1 - Adult living donor versus deceased donor liver transplantation

T2 - A 10-year prospective single center experience

AU - Fisher, Robert A.

AU - Cotterell, Adrian H.

AU - Maluf, Daniel

AU - Stravitz, Richard Todd

AU - Ashworth, April

AU - Nakatsuka, Mitsuru

AU - Sterling, Richard K.

AU - Luketic, Velimir A.

AU - Behnke, Martha K.

AU - Posner, Marc P.

PY - 2009/10/1

Y1 - 2009/10/1

N2 - It has been 4 years since the first, long-term (> 3 years) prospective comparison of adult-to-adult living donor liver transplantation (A2ALLTx) to adult deceased donor liver transplantation (ADDLTx) was reported.1 In this follow up, prospective, IRB approved, 10-year comparison of A2ALLTx to ADDLTx we expand on our initial observations. This data includes: age, gender, ethnicity, primary liver disease, waiting time, pretrans-plant CTP/MELD score, cold ischemia time (CIT), perioperative mortality, acute and chronic rejection, graft and patient survival, charges and post-transplant complications. In 10 years, 465 ADDLTx (81.3%) and 107 A2ALLTx (18.7%) were performed at VCUHS. Hepatitis C virus (HCV) was the most common reason for transplantation in both groups (54.5% vs. 48.2%). Data regarding overall patient and graft survival and retransplantation rates were similar. Comparison of patient/graft survivals, retransplantation rates in patients with and without HCV were not statistically different. A2ALLTx patients had less acute rejection (9.6% vs. 21.7%) and more biliary complications (27.1% vs. 17.6%). In conclusion, A2ALLTx is as durable a liver replacement technique as the ADDLTx. Patients with A2ALLTx were younger, had lower MELD scores, less acute rejection and similar histological HCV recurrence. Biliary complications were more common in A2ALLTx but were not associated with increased graft loss compared to ADDLTx.

AB - It has been 4 years since the first, long-term (> 3 years) prospective comparison of adult-to-adult living donor liver transplantation (A2ALLTx) to adult deceased donor liver transplantation (ADDLTx) was reported.1 In this follow up, prospective, IRB approved, 10-year comparison of A2ALLTx to ADDLTx we expand on our initial observations. This data includes: age, gender, ethnicity, primary liver disease, waiting time, pretrans-plant CTP/MELD score, cold ischemia time (CIT), perioperative mortality, acute and chronic rejection, graft and patient survival, charges and post-transplant complications. In 10 years, 465 ADDLTx (81.3%) and 107 A2ALLTx (18.7%) were performed at VCUHS. Hepatitis C virus (HCV) was the most common reason for transplantation in both groups (54.5% vs. 48.2%). Data regarding overall patient and graft survival and retransplantation rates were similar. Comparison of patient/graft survivals, retransplantation rates in patients with and without HCV were not statistically different. A2ALLTx patients had less acute rejection (9.6% vs. 21.7%) and more biliary complications (27.1% vs. 17.6%). In conclusion, A2ALLTx is as durable a liver replacement technique as the ADDLTx. Patients with A2ALLTx were younger, had lower MELD scores, less acute rejection and similar histological HCV recurrence. Biliary complications were more common in A2ALLTx but were not associated with increased graft loss compared to ADDLTx.

UR - http://www.scopus.com/inward/record.url?scp=77953380266&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=77953380266&partnerID=8YFLogxK

M3 - Article

VL - 8

SP - 298

EP - 307

JO - Annals of Hepatology

JF - Annals of Hepatology

SN - 1665-2681

IS - 4

ER -